Sunflower Pharmaceutical Group Co.,Ltd

Shenzhen Stock Exchange 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd Operating Cash Flow for the year ending December 31, 2023: USD 125.31 M

Sunflower Pharmaceutical Group Co.,Ltd Operating Cash Flow is USD 125.31 M for the year ending December 31, 2023, a -56.12% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Sunflower Pharmaceutical Group Co.,Ltd Operating Cash Flow for the year ending December 31, 2022 was USD 285.59 M, a 109.73% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Operating Cash Flow for the year ending December 31, 2021 was USD 136.17 M, a -24.02% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Operating Cash Flow for the year ending December 31, 2020 was USD 179.22 M, a 27.18% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Operating Cash Flow for the year ending December 31, 2019 was USD 140.92 M, a 11.89% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Shenzhen Stock Exchange: 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd

CEO	Ms. Yi Guan
IPO Date	Dec. 30, 2014
Location	China
Headquarters	Concentrated Area, Yingbin Road
Employees	5,776
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sunflower Pharmaceutical Group Co.,Ltd researches, develops, manufactures, and markets Chinese patent medicines in China. The company also produces chemical, biological, and health care medicines. Its products are used in therapeutic areas, such as pediatrics, gynecology, digestive system, respiratory and cold, rheumatism and bone disease, and cardiovascular and cerebrovascular. The company sells its products under the Sunflower and Little Sunflower brands. Sunflower Pharmaceutical Group Co.,Ltd was founded in 2005 and is based in Harbin, China.

Key trends

Past 5 years